Dianthus Therapeutics (NASDAQ:DNTH) Shares Down 6.8% – Here’s Why

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) was down 6.8% on Tuesday . The company traded as low as $25.04 and last traded at $25.21. Approximately 156,085 shares traded hands during mid-day trading, a decline of 55% from the average daily volume of 344,286 shares. The stock had previously closed at $27.04.

Wall Street Analyst Weigh In

A number of brokerages have commented on DNTH. TD Cowen began coverage on Dianthus Therapeutics in a research report on Friday, December 20th. They issued a “buy” rating on the stock. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Oppenheimer increased their target price on Dianthus Therapeutics from $48.00 to $52.00 and gave the stock an “outperform” rating in a research note on Monday, November 11th. Finally, Raymond James upgraded Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. Eight investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, Dianthus Therapeutics has an average rating of “Buy” and a consensus target price of $46.43.

Dianthus Therapeutics Stock Performance

The company has a market capitalization of $757.09 million, a P/E ratio of -10.23 and a beta of 1.74. The stock’s fifty day moving average price is $24.61 and its 200-day moving average price is $26.59.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.15). The firm had revenue of $2.17 million during the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. On average, research analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Hedge Funds Weigh In On Dianthus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. State Street Corp increased its stake in shares of Dianthus Therapeutics by 101.4% in the 3rd quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after purchasing an additional 413,425 shares during the last quarter. Janus Henderson Group PLC grew its position in Dianthus Therapeutics by 40.5% in the third quarter. Janus Henderson Group PLC now owns 949,334 shares of the company’s stock valued at $25,936,000 after acquiring an additional 273,670 shares during the last quarter. Point72 Asset Management L.P. raised its stake in Dianthus Therapeutics by 151.3% during the third quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after acquiring an additional 263,500 shares in the last quarter. Great Point Partners LLC lifted its holdings in shares of Dianthus Therapeutics by 21.3% in the second quarter. Great Point Partners LLC now owns 757,929 shares of the company’s stock worth $19,615,000 after acquiring an additional 132,929 shares during the last quarter. Finally, Braidwell LP grew its holdings in shares of Dianthus Therapeutics by 34.6% during the 3rd quarter. Braidwell LP now owns 493,687 shares of the company’s stock valued at $13,517,000 after purchasing an additional 126,836 shares during the last quarter. 47.53% of the stock is owned by institutional investors and hedge funds.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.